FDA approves room temperature storage of ZLB Behring's Helixate FS®

October 07, 2005

King of Prussia, PA--(BUSINESS WIRE)--Oct. 7, 2005 -- ZLB Behring announced today that Helixate FS has received approval to be stored at room temperature (up to 25 degrees C, 77 degrees F) for three months. The new storage guidelines for the treatment will provide users with greater flexibility and simplify storage options.

The United States Food and Drug Administration (FDA) approved the storage labeling change based on data from testing to assure the labeled potency (number of recombinant FVIII units contained in a vial) remains within specified limits through the expiration date of the product. The room temperature storage option is expected to be a significant convenience for Helixate FS users.

"This is great news to moms like me," said Rhonda Boni-Burden, mother of a child with hemophilia A. "This will allow greater flexibility when traveling and while attending sporting events. This really is a welcome convenience."

Starting in November 2005, each package of Helixate FS will include a special notification with details on the new labeling. While the new room temperature storage option may be used, ZLB Behring recommends refrigerating (2 degrees- 8 degrees C, 36 degrees- 46 degrees F) Helixate FS whenever possible. Please refer to the full prescribing information for Helixate FS for complete product information. If you have additional questions, please contact ZLB Behring Medical Information at 1-800-504-5434 or visit www.zlbbehring.com.
-end-
About Helixate FS

Helixate FS is a recombinant factor VIII treatment for hemophilia A that offers a more convenient administration by utilizing a 2.5 mL volume diluent, one of the smallest among available factor VIII products. Helixate FS does not use albumin in its purification or formulation and includes a solvent/detergent viral inactivation step. The most frequently reported adverse event was local injection site reactions. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Helixate FS. For additional details, see full prescribing information.

About Hemophilia

Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. About 17,000 Americans have hemophilia. The disease is caused by deficient or defective blood coagulation proteins, known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.

About ZLB Behring

ZLB Behring is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, ZLB Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. The company's broad portfolio of life-saving therapeutics is used in the treatment of individuals with hemophilia and other bleeding disorders, immune deficiency disorders and inherited emphysema; the prevention of hemolytic diseases for the newborn; cardiac surgery patients; and shock and burn victims. Additionally, ZLB Behring operates one of the world's largest, fully-owned plasma collection networks. ZLB Behring is a subsidiary of CSL Limited, a bio-pharmaceutical company, which operates worldwide from its headquarters in Melbourne, Australia. For more information, please visit www.ZLBBehring.com.

Edelman Public Relations

Related Hemophilia Articles from Brightsurf:

A new cell & gene therapy approach to treat common bleeding disorder
WFIRM researchers have developed an optimized cellular platform for delivering Factor 8 to better treat patients with hemophilia A.

Early treatment linked to reduced joint damage in young adults with severe hemophilia A
Children with severe hemophilia A who receive early prophylaxis are less likely to have joint damage in young adulthood than those who begin treatment later, according to a new study in Blood Advances.

Hemophilia three times more prevalent than thought
For the World Federation of Hemophilia, Iorio assembled an international team of researchers from France, US and UK to perform a meta-analysis of the registry data in countries with the most comprehensive registries of hemophilia, which were Australia, Canada, France, Italy, New Zealand and the UK.

Gene-based factor VIIa prevents bleeding episodes in animals with hemophilia
Hematology researchers have further refined how a treatment currently used on an urgent basis to control bleeding in hemophilia patients holds promise as a preventive treatment as well.

Single injection treats hemophilia B for life, in proof-of-concept study
Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor.

Groundbreaking gene therapy trial set to cure hemophilia
A 'cure' for hemophilia is one step closer, following results of a groundbreaking gene therapy trial led by Queen Mary University of London and the NHS in London.

Inflammatory factors linked to inhibition of factor VIII gene therapy in hemophilia A
As a gene therapy cure for hemophilia A moves closer to reality, a new study sheds light on a challenging complication in which a host autoimmune response inhibits the production of normal clotting factor VIII from the transferred FVIII gene.

Spark Therapeutics and Pfizer announce publication in The New England Journal of Medicine of Interim Data from phase 1/2 clinical trial of investigational gene therapy for Hemophilia B
Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc.

Disruptive technology for the treatment of hemophilia
An international team of hematologists including Guy Young, MD, of Children's Hospital Los Angeles, has found that in patients with hemophilia A with inhibitors, a novel therapy called emicizumab, decreases incidence of bleeding episodes by 87 percent.

Researchers improve vbectors for delivering hFVIII gene therapy to treat Hemophilia A
A new study examined 42 combinations of promoters and enhancers for human factor VIII (hFVIII) gene expression to identify the optimal adeno-associated virus (AAV)-based gene therapy delivery vector constructs to take forward into development.

Read More: Hemophilia News and Hemophilia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.